Last reviewed · How we verify
1+1
This drug is a combination of two substances, but no specific mechanism is known.
At a glance
| Generic name | 1+1 |
|---|---|
| Also known as | Dilaudid |
| Sponsor | Montefiore Medical Center |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Due to the lack of information, the exact mechanism of action for 1+1 is unknown.
Approved indications
Common side effects
Key clinical trials
- Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma (PHASE2)
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) (PHASE2)
- Phase I Trial of High-Density Theta Burst Stimulation (hdTBS) (PHASE1)
- Collection of Blood From Patients With Prostate Cancer
- Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)
- MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) (PHASE1)
- A Phase 1 Study of IM-1021 in Participants With Advanced Cancer (PHASE1)
- A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 1+1 CI brief — competitive landscape report
- 1+1 updates RSS · CI watch RSS
- Montefiore Medical Center portfolio CI